Medical Technology: FMC Lowers Outlook - China Restructuring Weighs
The operating result of the medical technology group is developing better than expected. However, the new CEO remains cautious and adjusts the forecast.
Fresenius Medical Care (FMC) has lowered its expectations for the full year after a significant decline in profit in the third quarter. The company's adjusted operating result is now expected to stagnate or decline by a mid-single-digit percentage in 2026, compared to previous expectations of growth. In the third quarter, FMC's net income fell by 42% to €160 million, while adjusted operating earnings decreased by 5% to €545 million.
The company's US business continues to struggle, with a 1.1% decline in treatment numbers in the third quarter.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
